| Recruiting | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (C NCT07026474 | Universität des Saarlandes | Phase 3 |
| Recruiting | Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent He NCT07213934 | University of Cincinnati | Phase 1 / Phase 2 |
| Recruiting | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Nec NCT06868433 | Emory University | Phase 1 |
| Recruiting | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returni NCT06589804 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058 | Emory University | N/A |
| Recruiting | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line P NCT06788990 | Bicara Therapeutics | Phase 2 / Phase 3 |
| Recruiting | Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Pr NCT06678724 | National Taiwan University Hospital | — |
| Recruiting | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregion NCT06699212 | Rakuten Medical, Inc. | Phase 3 |
| Recruiting | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, NCT06636734 | Emory University | Phase 2 |
| Recruiting | Identification of Pattern and Factors Affecting Recurrence in Head and Neck Carcinoma NCT06465030 | Sohag University | — |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC NCT06239220 | Glenn J. Hanna | Phase 2 |
| Withdrawn | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recur NCT05743270 | Replimune, Inc. | Phase 2 |
| Recruiting | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV N NCT06064877 | AVEO Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carci NCT05980000 | Washington University School of Medicine | Phase 2 |
| Recruiting | Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer NCT05945875 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer NCT05901545 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC NCT05726370 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy NCT05063552 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Withdrawn | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squam NCT05359692 | Incyte Biosciences International Sàrl | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) NCT05172258 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcin NCT04862650 | Marcelo Bonomi | Phase 2 |
| Active Not Recruiting | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic NCT04643379 | Washington University School of Medicine | Phase 2 |
| Completed | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC NCT05156970 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Recruiting | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treat NCT04671667 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamo NCT04862455 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery NCT04588038 | Hyunseok Kang, MD | Phase 1 |
| Withdrawn | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recu NCT04834349 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition NCT04454489 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing NCT04305795 | Rakuten Medical, Inc. | Phase 1 / Phase 2 |
| Completed | CIML NK Cell in Head & Neck Cancer NCT04290546 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer NCT04375384 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head NCT04220775 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC NCT03813836 | University College, London | Phase 2 |
| Terminated | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat NCT03823131 | Chase Heaton, MD | Phase 2 |
| Active Not Recruiting | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer NCT03468218 | Emory University | Phase 2 |
| Completed | Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Ca NCT03521570 | Emory University | Phase 2 |
| Terminated | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metasta NCT03522584 | University of Washington | Phase 1 / Phase 2 |
| Completed | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell NCT03422536 | University of Arizona | Phase 2 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Can NCT03032250 | Wake Forest University Health Sciences | N/A |
| Active Not Recruiting | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or NCT02955290 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT01602315 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Nec NCT01468896 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent NCT00494182 | M.D. Anderson Cancer Center | Phase 2 |